Medical devices, healthcare technology and the business of care
510(k) clearance · K262817

CrossFAST Integrated Microcatheter Advanced Delivery System

Vantis Vascular, Inc. · Decision date Sep 18, 2026

MEDTECHLEDGER EXPLANATIONK262817

What did the FDA decide?

Vantis Vascular, Inc. received a substantially equivalent (SESE) determination for the CrossFAST Integrated Microcatheter Advanced Delivery System under 510(k) K262817, dated September 18, 2026, with the submission received August 7, 2026. The device is a Class II percutaneous catheter under 21 CFR 870.1250, product code DQY, in the cardiovascular specialty. The FDA letter states the indications for use: access to discrete regions of the coronary and/or peripheral vasculature in conjunction with guide catheters, and placement of interventional devices.

SESE means the device may be marketed subject to general controls; it is not a PMA approval. The letter notes that a substantial equivalence determination does not establish compliance with other requirements of the Act, and it points to QMSR obligations and change-notification guidance. The public documentation does not include the predicate device identity, the summary of technological characteristics, or performance testing, so the basis for the equivalence finding is not described here.

Regulatory pathway
510(k) premarket notification
Clinical specialty
Cardiovascular
Decision date
Sep 18, 2026

FDA source record · MedtechLedger’s explanation describes the recorded change.

Regulatory record facts

Identifier
K262817
Regulatory pathway
510(k) premarket notification
Product code
DQY
Decision code
SESE
Decision date
Sep 18, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Catheter, Percutaneous.

Product code
DQY
FDA device class
2

FDA decision timeline

  1. K262817 received

    Application receipt date recorded by FDA.

  2. K262817 · FDA decision

    SESE

Related devices and submissions

Explore the linked device profile

No additional submissions with a verified PMA or product-code relationship are linked here.

Regulatory context

A 510(k) submission seeks a finding of substantial equivalence to a legally marketed device. A clearance and a PMA approval are different regulatory decisions.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Vantis Vascular, Inc.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
San Jose, CA

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records